References
- World Health Organization. The global burden of disease. 2004 update. Geneva: WHO; 2008.
- Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095–2128.
- Lawes CMM, Vander Hoorn S, Rodgers A, International Society of Hypertension. Global burden of blood-pressure-related disease, 2001. Lancet. 2008;371:1513–1518.
- Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2224–2260.
- Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomized trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:34–52.
- Leber PD, Davis CS. Threats to the validity of clinical trials employing enrichment strategies for sample selection. Control Clin Trials. 1998;19:178–187.
- Rothwell PM. Treating individuals 1 – external validity of randomized controlled trials: “To whom do the results of this trial apply?” Lancet. 2005;365:82–93.
- Caro JJ, Salas M, Speckman JL, et al. Persistence with treatment for hypertension in actual practice. CMAJ. 1999;160:31–37.
- Persson M, Carlberg B, Tavelin B, Lindholm LH. Doctors’ estimation of cardiovascular risk and willingness to give drug treatment in hypertension: fair risk assessment but defensive treatment policy. J Hypertens. 2004;22:65–71.
- Shortliffe EH. The evolution of electronic medical records. Acad Med. 1999;74:414–419.
- Persson M, Bohlin J, Eklund P. Development and maintenance of guideline-based decision support for pharmacological treatment of hypertension. Comput Methods Programs Biomed. 2000;61:209–219.
- Ludvigsson JF, Andersson E, Ekbom A, et al. External review and validation of the Swedish national inpatient register. BMC Public Health. 2011;11:450.
- Appelros P, Terent A. Validation of the Swedish inpatient and cause-of-death registers in the context of stroke. Acta Neurol Scand. 2011;123:289–293.
- Koster M, Asplund K, Johansson A, Stegmayr B. Refinement of Swedish administrative registers to monitor stroke events on the national level. Neuroepidemiology. 2013;40:240–246.
- Glasgow RE, Lichtenstein E, Marcus AC. Why don’t we see more translation of health promotion research to practice? Rethinking the efficacy-to-effectiveness transition. Am J Public Health. 2003;93:1261–1267.
- Flay BR. Efficacy and effectiveness trials (and other phases of research) in the development of health promotion programs. Prev Med. 1986;15:451–474.
- Greenwald P, Cullen JW. The new emphasis in cancer control. J Natl Cancer Inst. 1985;74:543–551.
- Thelin N, Holmberg S, Nettelbladt P, Thelin A. Mortality and morbidity among farmers, nonfarming rural men, and urban referents a prospective population-based study. Int J Occup Environ Health. 2009;15:21–28.
- Gyllerup S, Lanke J, Lindholm LH, Schersten B. High coronary mortality in cold regions of Sweden. J Intern Med. 1991;230:479–485.
- Norberg M, Wall S, Boman K, Weinehall L. The Vasterbotten Intervention Programme: background, design and implications. Global Health Action. 2010;3:4643. doi: 10.3402/gha.v3i0.4643.